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Natural killer T cellAlpha-galactosylceramide (αGC), a lipid antigen present on CD1d molecules, is predicted to have clinical
applications as a new class of adjuvant, because αGC strongly activates natural killer T (NKT) cells which pro-
duce large amounts of IFN-γ. Here, we incorporated αGC into stearylated octaarginine-modiﬁed liposomes
(R8-Lip), our original delivery system developed for vaccines, and investigated the effect of nanoparticulation.
Unexpectedly, the systemic administered R8-Lip incorporatingαGC (αGC/R8-Lip) failed to improve the immune
responsesmediated byαGC comparedwith solubleαGC in vivo, althoughαGC/R8-Lip drastically enhancedαGC
presentation on CD1d in antigen presenting cells in vitro. Thus, we optimized theαGC/R8-Lip in vivo to overcome
this inverse correlation. In optimization in vivo, we found that size control of liposome and R8-modiﬁcationwere
critical for enhancing the production of IFN-γ. The optimization led to the accumulation of αGC/R8-Lip in the
spleen and a positive therapeutic effect against highly malignant B16 melanoma cells. The optimized αGC/
R8-Lip also enhanced αGC presentation on CD1d in antigen presenting cells and resulted in an expansion in
the population of NKT cells. Herein, we show that R8-Lip is a potent delivery system, and size control and
R8-modiﬁcation in liposomal construction are promising techniques for achieving systemic αGC therapy.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Alpha-galactosylceramide (αGC) is a unique adjuvant that enables
the activation of both speciﬁc and non-speciﬁc immune responses. In
general, adjuvants such as the toll-like receptor ligand activate innate
immunity via the production of inﬂammatory cytokines and type I in-
terferon (IFN). On the other hand, αGC activates innate and adaptive
immunity via the production of large amounts of INF-γ, which would
be expected to show antitumor activity independent of the speciﬁc
class of tumor [1]. αGC, a synthetic glycolipid, is presented by CD1d
molecules, antigen-presenting molecules, to invariant natural killer
T (NKT) cells [2–4]. NKT cells recognize the resulting αGC/CD1d
complex via semi-invariant T cell receptors (Vα14-Jα18 in mice;
Vα24-Jα18 in humans), resulting in activation. The semi-invariant T
cell receptor of NKT cells confers an important advantage in αGC
therapy, because there is very little individual difference between T
cell receptors, and, because of this, the effect would be similar,Sciences, Hokkaido University,
el.: +81 11 706 3919; fax: +81
arashima).
V. . Open access under CC BY-NC-ND liirrespective of patient. Thus, it is expected as versatile cancer immune
therapy to have an effect on all patients. The therapeutic value of NKT
cells was ﬁrst discovered in studies using αGC in a metastatic tumor
model, which prevents the metastasis of intravenously infected B16
melanoma cells in the lungs of mice [2,5]. This protection activity is
dependent on the production of large amounts of INF-γ from NKT
cells and on the activation of NK cells and killer T cells, but not on
the direct effect of NKT cells themselves [6]. Owing to its unique
and strong antitumor ability, many pre-clinical and clinical studies
of αGC as KRN7000 were initiated. KRN7000, which is now in clinical
trials, contains sucrose, L-histidine and Tween20 as a dispersant. The
clinical responses varied, depending on the therapeutic approach
used, such as the direct injection of αGC and cell therapies using DC
or NKT cells [7]. Although an intravenous administration of soluble
αGC did not result in measurable clinical beneﬁts, the intravenous
injection of αGC-loaded dendritic cells (DCs) led to an increase in
serum levels of IL-12 and IFN-γ and an expansion of the NKT cell pop-
ulation in lung cancer and head and neck cancer patients [8–12]. In
other words, while αGC has few effects in in vivo direct treatments,
it appears to be effective in ex vivo cell therapies. These results clearly
suggest that solubleαGC is not taken up efﬁciently by antigen presenting
cells (APCs). Hence, to induce a sufﬁcient immune response by the sys-
temic administration of αGC, it will be necessary to control the disposi-
tion and cellular uptake of αGC with the currently available delivery
systems. In addition, development of delivery systems which achievecense.
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therapy. The therapeutic effects of DC therapy using αGC are dependent
on the accession efﬁciency of administered DCs, that is, applications of
DC therapy against diseases, other than lung cancer and head and neck
cancer, would likely be difﬁcult. On the other hand, it is expected that
delivery systems that involve the systemic administration of αGC will
be applicable to diseases other than lung cancer and head and neck can-
cer, because the delivery systems could be used to control the tissue
distribution of αGC.
In a previous study, we reported on the potential of stearylated
octaarginine-modiﬁed liposomes (R8-Lip) as a vaccine delivery sys-
tem [13–16]. Octaarginine (R8) is a cell-penetrating peptide (CPP).
CPPs can be useful for delivering various molecules to cells [17]. The
R8 peptide was conjugated with a stearyl moiety and the resulting
stearylated R8 (STR-R8) was attached to the liposomal surface, a pro-
cess that permitted the ﬂexibility and function of the R8 peptide to be
maintained [18,19]. R8-Lip in which ovalbumin is encapsulated as a
protein antigen, was efﬁciently taken up by dendritic cells (DCs)
and induced strong antigen presentation via MHC class I molecules
in vitro, suggesting that R8-Lip has the potential for serving as a po-
tent carrier for delivering antigens to DCs [13]. In addition to protein
antigens, we also reported on the efﬁcient delivery of lipid antigens,
such as glucose monomycolate and glycerol monomycolate, and the
induction of immune responses via CD1 antigen presentation after
subcutaneous injection in vivo [15,16]. Although we have generally
demonstrated the utility of R8-Lip as a vaccine delivery system for
the in vitro targeting of DCs and subcutaneous immunization, an ap-
plication of R8-Lip for systemic immunization, the issue of whether
it can be used in systemic immunization, namely intravenous admin-
istration has not been addressed. Moreover, very few studies have
been devoted to examining adjuvant effects of αGC by incorporating
αGC into delivery systems [20–22]. In particular, the effect of liposomal
αGC against tumors and the mechanism responsible for the immune
responses mediated by liposomal αGC remain unveriﬁed.
In this study, we incorporated αGC into R8-Lip and investigated
the potential of R8-Lip as a delivery system for αGC therapy via a sys-
temic treatment. In in vitro experiments, we conﬁrmed the efﬁciency
of αGC presentation on CD1d molecules in JAWSII cells, a cell line of
murine DCs. In in vivo experiments, optimization of the R8-Lip incorpo-
rating αGC (αGC/R8-Lip) was performed to control the biodistribution
of the R8-Lip, especially for spleen targeting, based on the production of
IFN-γ in serum. The therapeutic effect of the optimized αGC/R8-Lip
against lung metastasis was then examined in highly malignant B16
melanoma cells. To conﬁrm that the immune responses caused by
αGC/R8-Lip occurred via αGC machinery, we also investigated αGC
presentation on CD1d in APCs and theNKTpopulation after the systemic
administration of αGC/R8-Lip. The ﬁndings reported herein indicate
that the nanoparticulation of αGC by R8-Lip drastically enhanced
immune responses via the αGC machinery, when the materials were
systemically administered.
2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (EPC) and N-(Carbonyl-methoxypoly-
ethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine
(DSPE-PEG2000) were purchased from NOF Corporation (Tokyo, Japan).
Cholesterol (Chol) was purchased from AVANTI Polar Lipids Inc.
(Alabaster, AL, USA). STR-R8 was synthesized by KURABO (Osaka,
Japan). αGC (KRN7000) was obtained from Funakoshi Co. Ltd. (Tokyo,
Japan). [3H] cholesteryl hexadecyl ether (CHE) was purchased from
PerkinElmer Co. Ltd. (Waltham, MA, USA). Anti-mouse alpha GalCer:
CD1d Complex PE was purchased from eBioscience (San Diego, CA,
USA). Alexa Fluor 647 anti-mouse I-A/I-E, PE/Cy7 anti-mouse CD19,
FITC anti-mouse CD3 and each of the isotype controls were obtainedfrom BioLegend (San Diego, CA, USA). Mouse CD1d Tetramer-SA-PE
was purchased from MBL International (Woburn, MA, USA).2.2. Cells and animals
JAWSII cells derived from murine dendritic cells were purchased
from the American Type Culture Collection (Manassas, VA). JAWSII
cell was cultured byα-MEM (SIGMA-Aldrich, St. Louis, MO) containing
20% FBS, 100 U/ml penicillin-streptomycin, 4 mmol/l L-grutamine,
1 mmol/l sodium pyruvate and 5 ng/ml GM-CSF. B16-F10 murine
melanoma cells stably expressing luciferase (GL4) (B16-F10-luc2;
Caliper Life Sciences, MA, USA) were grown in 10% FBS in RPMI-
1640 (SIGMA-Aldrich, St. Louis, MO). C57BL/6 (H-2b) female mice (6
to 8 weeks old) were obtained from Japan SLC, Inc. (Shizuoka, Japan).
Experiments using mice were approved by the Pharmaceutical Science
Animal Committee of Hokkaido University.2.3. Preparation of liposomes incorporating αGC
Liposomes were composed of EPC, Chol and STR-R8 (70:30:5
molar ratio). DSPE-PEG2000 was included in some cases. 560 nmol
of EPC, 240 nmol of Chol, 40 nmol STR-R8 or/and 8, 16, 40 nmol of
DSPE-PEG2000 in chloroform solutions were initially mixed in a test
tube and 100 μg (117 nmol) of αGC was then added. The solvent
was removed with a stream of nitrogen to produce a lipid ﬁlm.
0.2 ml of 10 mmol/l HEPES (pH 7.4) was added to the lipid ﬁlm,
and the mixture was incubated for 30 min at room temperature to hy-
drate the ﬁlm. The hydrated lipid ﬁlm was then mixed to produce lipo-
somes. The liposome suspension was extruded through polycarbonate
membrane ﬁlters (400-nm, 800-nmor 1000-nmpore size; Nucleopore)
with a Mini-Extruder (Avanti Polar Lipids Inc., Alabaster, AL, USA) for
sizing of liposomes. In the case of αGC/R8-Lip (unoptimized), the lipo-
some suspension was sonicated in a bath type sonicator instead of
using an extrusion step. The solutions after extrusion or sonication
were used as liposome samples. These liposomes are used for experi-
ments within 2 days of their preparation. The concentrations of lipid
were determined by means of a phospholipid assay kit (Wako, Osaka,
Japan). The lipid concentration of liposomes without extrusion was
3.9 mM, while the lipid concentration and yield of extruded liposomes
were 2.1 mMand 61%, respectively. The incorporation ratio ofαGC into
a liposome is considered to be 100%, because αGC appears to act as a
lipid (EPC and Chol). The αGC concentrations in liposome solutions
were calculated from the phospholipid concentration. TheαGC concen-
trations of liposomes without or with extrusion were calculated to be
0.48 mg/ml and 0.26 mg/ml, respectively. The diameter of the lipo-
somes was measured by dynamic light scattering, and zeta potentials
were determined by laser-Doppler velocimetry with a ZETASIZER
Nano (ZEN3600, Malvern Instruments Ltd., Malvern, WR, UK).2.4. αGC presentation on CD1d in JAWSII cell
2 × 105 JAWSII cells were cultured in a 6-well plate for 48 h. The
cells were washed with phosphate buffer saline (PBS), and the medi-
um was then replaced with 1 ml of serum-free medium containing
αGC/R8-Lip or soluble αGC. Soluble αGC is prepared as a solution of
1 mg/ml in 100% DMSO with heating at 80 °C for several minutes.
The solution of 1 mg/ml in DMSO was diluted to more than 100
times with medium. The ﬁnal concentration of DMSO in the medium
was less than 1%. The cells were then incubated for 3 h. Thereafter, the
medium was replaced with fresh medium containing 20% serum, and
incubated for an additional 21 h. After the incubation, the cells were
washed with PBS and collected into tubes. The cells were stained with
anti-mouse alpha GalCer:CD1d Complex PE. The ﬂuorescence of stained
cells was measured by FACSCalibur (BD Biosciences).
Fig. 1. Presentation of α-galactosylceramide (αGC) via CD1d molecules in JAWSII cells.
JAWSII cells were cultured with soluble αGC or octaarginine-modiﬁed liposome incor-
porating αGC (αGC/R8-Lip). After 24 h, the cells were collected and stained with an
anti-αGC:CD1d antibody. The stained cells were analyzed by ﬂow cytometry. (a) Typical
histograms of non-treated cells (black), soluble αGC treated cells (pink) and αGC/
R8-Lip treated cells (blue) at a dose of 1000 ng/ml αGC. (b) The percent of anti-αGC/
CD1d positive cells at several doses ofαGC. Values are themean ± SDof at least three dif-
ferent experiments (**P b 0.01).
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C57BL/6 mice were intravenously injected with each sample
equivalent to 5 μg of αGC into the tail. Soluble αGC was prepared
by dissolving in PBS containing 5.6% sucrose, 0.75% L-histidine and
0.5% Tween20 with heating at 80 °C for several minutes. The volume
injected was 200 μl. After 18 h, blood samples were collected from
the heart using needle and syringe. After allowing the blood to clot,
the samples were centrifuged. The supernatants were used as serum
samples. IFN-γ level in serum was measured by an ELISA kit (R&D
systems, Basel, Switzerland). These experiments were carried out fol-
lowing the manufacturer's instructions.
2.6. Pharmacokinetic analysis of the liposomes
0.25 nmol of cholesteryl hexadecyl ether, [cholesteryl-1,2-3H(N)]-
([3H] CHE, 40 Ci/mmol) was added, when lipid ﬁlm was prepared. The
amount of [3H] CHE was 0.03 mol% of total lipids. Liposomes including
[3H] CHE were injected into the tail vein of C57BL/6 mice at a dose of
5 μg αGC. Injected volume was 200 μl. The mice were sacriﬁced 10, 30
and 90 min after the injection and blood, lung, liver and spleen were
collected. To determine the actual uptake of liposomes in tissues,
the liposomes in the vascular space was removed by perfusion.
After weighing the samples, they were dissolved in Soluene-350
(PerkinElmer, Waltham, MA, USA) overnight at 50 °C. The radioac-
tivities of the samples were determined by liquid scintillation
counting, after adding 10 ml of scintillation ﬂuid (Hionic Fluor,
PerkinElmer, Waltham, MA, USA).
2.7. Anti-tumor effects in lung metastatic tumor models
On day 0, 2 × 105 cells of B16-F10-luc2 in 200 μl of PBS were
injected into the tail vein of C57BL/6 mice. On day 4, soluble αGC
and liposome (injected volume: 200 μl) were intravenously injected
at a dose of 5 μg αGC into the tail. Soluble αGC was prepared as
described in Section 2.5. On day 19, the mice were sacriﬁced, and
the lungs were collected. For the quantiﬁcation of tumor metastasis,
the collected lungs were completely homogenized using a POLYTRON
homogenizer (KINEMATICA, Littan, Switzerland) in 1 ml of lysis buffer
(100 mMTris–HCl, 2 mMEDTA, 0.1% TritonX-100, pH 7.8). The luciferase
activitieswere thenmeasured using a luminometer (Luminescencer-PSN,
ATTO, Japan). Luciferase activities are expressed as relative light units
(RLU) per whole lung.
2.8. αGC presentation on CD1d in antigen presenting cells in vivo
Soluble αGC and liposome (injected volume: 200 μl) were intrave-
nously injected at a dose of 5 μgαGC into the tail. SolubleαGCwas pre-
pared as described in Section 2.5. After 15 h, the spleenswere collected,
and splenocytes were prepared. 2 × 106 splenocyte cells were stained
by anti-mouse alpha GalCer:CD1d Complex PE and Alexa Fluor 647
anti-mouse I-A/I-E. The ﬂuorescence of stained cells was measured by
FACSCalibur (BD Biosciences).
2.9. Population of NKT cells in vivo
Soluble αGC and liposome (injected volume: 200 μl) were intra-
venously injected at a dose of 5 μg αGC into the tail. Amount of
injected liposomes was 40 nmol. Soluble αGC was prepared as
described in Section 2.5. After 3 days, the spleens were collected,
and splenocytes were isolated. 1 × 107 splenocyte cells were stained
by PE/Cy7 anti-mouse CD19, FITC anti-mouse CD3 and mouse CD1d
Tetramer-SA-PE. The ﬂuorescence of stained cells was measured by
FACSCalibur (BD Biosciences). NKT cell population was identiﬁed as
CD19−/CD3+/CD1d tetramer+ cells.2.10. Statistical analysis
Pair-wise comparisons between treatmentsweremade using an un-
paired t-test. Comparisons between multiple treatments were made by
one-way analysis of variance, followed by the Tukey–Kramer test. A
P value of b0.05 was considered to be a signiﬁcant difference.
3. Results
3.1. Efﬁciencies of αGC presentation on CD1d in JAWSII cells
αGC is presented on CD1dmolecules after being taken up by APCs.
We ﬁrst investigated the efﬁciencies of the antigen presentation of
αGC on CD1d by αGC/R8-Lip in JAWSII cells, a cell line of mouse den-
dritic cells. In this experiment, we used a αGC/R8-Lip preparation
that was composed of EPC, Chol and STR-R8 (molar ratio: 70/30/5).
The diameter, zeta potential and polydispersity index (PDI) of the
αGC/R8-Lip particles were 98 nm, 40 mV and 0.204, respectively.
The αGC/R8-Lip was pulsed to JAWSII cells. Non-liposomal αGC
(soluble αGC) was conventionally prepared by dissolving αGC in
DMSO and was used in in vitro experiments. The JAWSII cells were
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ﬂow cytometry. As a result, the histogram of cells treated with αGC/
R8-Lip was shifted drastically, compared to that of non-treated cells
and cells that had been treated with soluble αGC (Fig. 1a). Fig. 1b
shows the percent of anti-αGC/CD1d positive cells, namely the per-
cent of cells presentingαGC on CD1d. The αGC presentations induced
by the αGC/R8-Lip increased in a dose-dependent manner and were
signiﬁcantly higher than the corresponding values for soluble αGC
(Fig. 1b). Moreover, the value of αGC/R8-Lip at 100 ng/ml was compa-
rable to that of soluble αGC at a concentration of 10000 ng/ml,
suggesting that the efﬁciency of αGC presentation by αGC/R8-Lip was
2 orders of magnitude higher in comparison with that of soluble αGC
(Fig. 1b). Thus, as shown in Fig. 1, R8-Lip efﬁciently delivers αGC to
APCs and induces a strong αGC presentation on CD1d.
3.2. INF-γ production of αGC/R8-Lip after intravenous administration in
vivo
αGC induced the production of IFN-γ from NKT cells via CD1d pre-
sentation by APCs [2,23]. We next examined the production of IFN-γ
after the intravenous administration of αGC/R8-Lip in mice. Mice
were intravenously administered soluble αGC or αGC/R8-Lip. After
18 h, serum samples were collected and the concentrations of IFN-γ
were determined by ELISA. Unexpectedly, the concentration of IFN-γ
after the αGC/R8-Lip treatment was similar to that of soluble αGC
(Fig. 2). This result indicates that the mere modiﬁcation of R8 for efﬁ-
cient cellular internalization is inefﬁcient for enhancing αGC therapy
via systemic injection.
3.3. Optimization of αGC/R8-Lip in vivo
To overcome the inverse correlation (Fig. 2), we optimized αGC/
R8-Lip by controlling the pharmacokinetics of the process, based on
the production of IFN-γ in vivo. The spleen is a major target tissue
for immunization via intravenous administration. The surface of the
particles was modiﬁed with PEG and the size of the liposomes was
controlled, in an attempt to improve the action of αGC/R8-Lip. PEG
modiﬁcation leads to the stabilization of liposomes and the suppres-
sion of non-speciﬁc interactions. In addition, the size of nano particlesFig. 2. The production of IFN-γ after intravenous administration of octaarginine-
modiﬁed liposome incorporating α-galactosylceramide (αGC/R8-Lip). Each sample at
a dose of 5 μg αGC was intravenously administered to mice. After 18 h, serum samples
were collected and IFN-γ concentrations of sera were measured by ELISA. Values are
the mean ± SD (n = 3, N.S.: no signiﬁcant difference).is an important factor when the spleen is a target for the uptake by
APCs [24]. αGC/R8-Lip was modiﬁed with DSPE-PEG2000 at 1 mol%,
2 mol% and 5 mol% of the total lipid. The diameter, PDI and zeta-
potential were determined to be as follows: 1 mol% of DSPE-PEG2000
(85 nm, 0.219, 29 mV), 2 mol% of DSPE-PEG2000 (99 nm, 0.273,
20 mV), and5 mol% of DSPE-PEG2000 (94 nm, 0.263, 19 mV). Although
2 mol% of DSPE-PEG2000 modiﬁed αGC/R8-Lip (αGC/R8/2%PEG-Lip)
resulted in a slight increase in the production of IFN-γ, modiﬁcation of
1 mol% and 5 mol% of DSPE-PEG2000 to αGC/R8-Lip impaired the pro-
duction of IFN-γ (Fig. 3a). We next controlled the size of the αGC/R8/
2%PEG-Lip by passing the particles through 400-nm, 800-nm and
1000-nm of polycarbonate membrane ﬁlters. The sizes of the αGC/R8/
2%PEG-Lip particles were 158 nm (400-nm ﬁlter; PDI 0.211; 25 mV),Fig. 3. Optimization of octaarginine-modiﬁed liposome incorporating
α-galactosylceramide (αGC/R8-Lip). Each sample at a dose of 5 μg αGC was intrave-
nously administered to mice. After 18 h, serum samples were collected and IFN-γ con-
centrations of sera were measured by ELISA. (a) Optimization of ratio of polyethylene
glycol (PEG) modiﬁcation into αGC/R8-Lip. αGC/R8-Lip was modiﬁed with PEG at
1 mol%, 2 mol% and 5 mol% of total lipids. (b) Size effect of R8/2% PEG-modiﬁed lipo-
some incorporating αGC (αGC/R8/2%PEG-Lip). The sizes of αGC/R8/2%PEG-Lip were
controlled by passage through 400-nm, 800-nm and 1000-nm ﬁlters. (c) The produc-
tion of IFN-γ by optimized αGC/R8-Lip (αGC/R8/2%PEG-Lip sized by 800-nm ﬁlter)
was compared to those of soluble αGC and unoptimized αGC/R8-Lip. And the effects
of PEG, R8 and αGC on the production of IFN-γ were conﬁrmed in the optimized
αGC/R8-Lip. Values are the mean ± SD (n = 3–6, *P b 0.05, **P b 0.01).
Fig. 4. The biodistribution of octaarginine-modiﬁed liposome incorporating
α-galactosylceramide (αGC/R8-Lip, unoptimized) and R8/2% polyethylene glycol mod-
iﬁed liposome incorporating αGC (αGC/R8/PEG-Lip, optimized). αGC/R8-Lip and αGC/
R8/PEG-Lip labeled with [3H] CHE were injected intravenously into mice. After 10, 30
and 90 min, the mice were sacriﬁced and the distributions of the liposomes were eval-
uated. Biodistribution is expressed as the percentage of the injected dose per organ
(%ID/organ). (a) Blood, lung, liver and spleen. (b) The fold increase of optimization is
expressed as the organ distribution of αGC/R8/PEG-Lip per that of αGC/R8-Lip (αGC/
R8/PEG-Lip/αGC/R8-Lip). Values are the mean ± SD (n = 3, *P b 0.05, **P b 0.01).
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PDI 0.286; 28 mV), respectively. As shown in Fig. 3b, although control-
ling the size using ﬁlters promoted the production of IFN-γ, the αGC/
R8/2%PEG-Lip that was sized by the 800-nm ﬁlter showed the highest
promotion effect. The promotion effect of the αGC/R8/2%PEG-Lip that
was sized using an 800-nm ﬁlter was more than 5 times greater than
that of soluble αGC and the unoptimized αGC/R8-Lip (Fig. 3c). That is,
the production of IFN-γ was substantially escalated by optimizing par-
ticle diameter by size control. In the case of αGC/R8/PEG-Lip without
R8, the production of IFN-γ was signiﬁcantly decreased, although the
αGC/R8/2%PEG-Lip without PEG showed a slightly low value of IFN-γ
of αGC/R8/2%PEG-Lip (Fig. 3c). This result indicates that R8 modiﬁca-
tion also affects to the efﬁcient production of IFN-γ. Consequently,
we used the αGC/R8/2%PEG-Lip sized by passage through an
800-nm ﬁlter as the optimized αGC/R8-Lip (αGC/R8/PEG-Lip) in
subsequent experiments.
3.4. Tissue distribution of αGC/R8-Lip and αGC/R8/PEG-Lip
To determine the inﬂuence of optimization in the pharmacokinetics
of the process, we examined the tissue distribution of αGC/R8-Lip
(unoptimized) and αGC/R8/PEG-Lip (optimized), labeled with [3H] CHE,
at 10, 30 and 90 min after intravenous administration, followed by
blood perfusion. As shown in Fig. 4a, althoughαGC/R8-Lip accumulated
in the liver in a time-dependent manner, the accumulation of αGC/R8/
PEG-Lip in the liver was suppressed and it rapidly accumulated in the
spleen. Of note, the fold increase in the accumulation of αGC/R8/
PEG-Lip in the spleen, calculated as the organ distribution of αGC/R8/
PEG-Lip divided by that of αGC/R8-Lip, was signiﬁcantly higher
compared with other organs (Fig. 4b). Thus, these results show that
the αGC/R8/PEG-Lip induced a rapid accumulation in the spleen,
suggesting that the rapid accumulation of αGC in the spleen by αGC/
R8/PEG-Lip stimulated the production of IFN-γ.
3.5. Antitumor effect of αGC/R8/PEG-Lip against lung metastases model
We then investigated the antitumor effect of αGC/R8/PEG-Lip
against B16 melanoma cells, a lung metastatic model. Mice were
intravenously grafted with 2 × 105 B16-F10-luc cells, a highly malig-
nant and highly metastatic type of melanoma, and soluble αGC and
αGC/R8/PEG-Lip were intravenously administered after 4 days
(Fig. 5a). As shown in Fig. 5b, no macroscopic antitumor effects
were observed in the lungs of the soluble αGC treated group. On
the other hand, the treatment of αGC/R8/PEG-Lip clearly inhibited
lung metastasis (Fig. 5b). In addition to the macroscopic observa-
tions, the amount of lung metastasis was quantitatively examined
by measuring luciferase activities in the lung. No signiﬁcant
antitumor effect was observed in the soluble αGC treated group
compared to the non-treatment group (Fig. 5c). To the contrary,
αGC/R8/PEG-Lip treatment signiﬁcantly inhibited lung metastasis
in comparison with non-treatment and the treatment with soluble
αGC (Fig. 5c). The inhibition effect of lung metastasis in the αGC/
R8/PEG-Lip treated group was more than 65% (Fig. 5c). Therefore,
these ﬁndings suggest that αGC/R8/PEG-Lip has antitumor effects
against lung metastasis mediated by a highly malignant melanoma.
3.6. αGC/R8/PEG-Lip enhances αGC presentation on CD1d in APCs in vivo
We examined the issue of whetherαGC presentation on CD1d was
promoted by an in vivo αGC/R8/PEG-Lip treatment. Mice were intra-
venously treated with soluble αGC or αGC/R8/PEG-Lip and the
splenocytes were stained by anti-major histocompatibility complex
(MHC) class II and anti-αGC/CD1d antibodies after 15 h. Fig. 6a
shows typical dot plots for each group. The area in the upper right
shows the distribution of cells stained by both anti-MHC class II and
anti-αGC/CD1d antibodies. The valueswere subtracted from the values
Fig. 5. Therapeutic effects on experimental lung metastasis model with B16-F10 mela-
noma. (a) Experimental scheme. B16-F10 melanoma cells stably expressing luciferase
(B16-F10-luc2) were intravenously inoculated to mice. After 4 days, soluble
α-galactosylceramide (αGC) or octaarginine/2% polyethylene glycol-modiﬁed lipo-
some incorporating αGC, which was passed through 800 nm ﬁlter (αGC/R8/PEG-Lip)
were intravenously injected at a dose of 5 μg αGC. On day 19, the lungs were collected.
(b) Pictures of the lungs collected on day 19. (c) Quantitative analysis of lung metasta-
sis by measuring luciferase activities. For the quantiﬁcation of tumor metastasis, the
collected lungs were completely homogenized and the luciferase activities were then
measured. Luciferase activities are expressed as relative light units (RLU) per whole
lung. Values are the mean ± SD (n = 5–7, *P b 0.05, **P b 0.01).
Fig. 6. Antigen presentation of α-galactosylceramide (αGC) on CD1d molecules in an-
tigen presenting cells (APCs). Mice were intravenously administered soluble αGC or
octaarginine/2% polyethylene glycol-modiﬁed liposome incorporating αGC, which
was passed through an 800 nm ﬁlter (αGC/R8/PEG-Lip) at a dose of 5 μg αGC. After
18 h, the spleens were collected and the single cell suspensions of splenocyte were pre-
pared. The cell suspensions were then stained by anti-MHC class II (MHC-II) antibody
(Alexa Fluor 647) and anti-alpha GalCer:CD1d Complex antibody (phycoerythrin) and
were analyzed by ﬂow cytometer. APCs presenting αGC on CD1d were identiﬁed as
MHC-II+/GalCer:CD1d+ cells. (a) Typical dot plots of the splenocyte derived from
non-treated mouse, soluble αGC treated mouse and αGC/R8/PEG-Lip treated mouse.
The numbers in the upper right area indicate the percentage of MHC-II+/GalCer:CD1d+
cells. (b) The percentages of anti-αGC/CD1d positive cells. Values are the mean ± SD
(n = 3, *P b 0.05).
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PEG-Lip treated group, a signiﬁcantly increased number of cells were
stained by anti-MHC class II and anti-αGC/CD1d, although the soluble
αGC treated group was not (Fig. 6b). Hence, this suggests that αGC/
R8/PEG-Lip enhances αGC presentation on CD1d in APCs in vivo.
3.7. Intravenous administration of αGC/R8/PEG-Lip increases the popula-
tion of NKT cells in vivo
Lastly, we conﬁrmed that a population of NKT cells was located in
the spleen after the administration of soluble αGC or αGC/R8/
PEG-Lip. After NKT cells recognized the αGC/CD1d complex on APCs
via T cell receptors, the NKT cells activate and proliferate. It has
been reported to occur rapidly (8–24 h) after the administration of
αGC and NKT cells can no longer be detected by tetramer staining.
The NKT cells then expanded, reaching maximal levels at 3 days [25].
Mice were intravenously treated with soluble αGC or αGC/R8/PEG-Lip
and splenocytes were obtained and stained by an anti-CD19 antibody,
an anti-CD3 antibody and a CD1d tetramer after 3 days. The NKT cell
population was identiﬁed as CD19−/CD3+/CD1d tetramer+ cells.
Fig. 7a shows typical dot plots for each. The numbers in the upper
right area in Fig. 7a indicate the percentage of CD3+/CD1d tetramer+
cells among the CD19− cells. The values are subtracted from the values
of each isotype control from the values of each sample. The NKTpopulations in αGC/R8/PEG-Lip treated groups were drastically higher
than the corresponding values for the non treated group and the soluble
αGC treated groups (Fig. 7b). These data conﬁrm that αGC/R8/PEG-Lip
treatment efﬁciently expanded the population of NKT cells. Meanwhile,
the results shown in Figs. 6 and 7 indicate thatαGC/R8/PEG-Lip induces
immune responses via a αGC-mediated mechanism.
4. Discussion
As noted in the introduction, the purpose of the present study was
to evaluate the potential for the use of R8-Lip as a delivery system for
αGC to achieve efﬁcient αGC therapy via systemic administration.
Although very few reports have been devoted to investigating the
adjuvant effects of αGC by using delivery systems, particularly lipo-
somes [20–22], the enhancement of adjuvant effects ofαGC by using li-
posomes is clearly demonstrated in this study. This is the ﬁrst report to
show the antitumor effect ofαGC incorporated liposomes against a B16
lung metastatic model.
We ﬁrst showed that the αGC/R8-Lip preparation induced a sig-
niﬁcantly higher αGC antigen presentation on CD1d in JAWSII cells
than soluble αGC (Fig. 1). αGC is presented on CD1d in endosomes
and lysosomes after internalization by APCs [26]. We hypothesized
that this is achieved by the efﬁcient cellular uptake and control of in-
tracellular trafﬁcking aided by αGC/R8-Lip. The surface of the αGC/
R8-Lip liposomes was modiﬁed with STR-R8. Several reports have
Fig. 7. Population of natural killer T (NKT) cells in the spleen after administration
of octaarginine/2% polyethylene glycol-modiﬁed liposome incorporating α-
galactosylceramide, which was passed through 800 nm ﬁlter (αGC/R8/PEG-Lip).
Mice were intravenously administered soluble αGC or αGC/R8/PEG-Lip at a dose of
5 μg αGC. After 3 days, the spleens were collected and the single cell suspensions of
splenocytes were prepared. The cell suspensions were then stained with an anti-CD19
antibody (PE/Cy7), anti-CD3 antibody (FITC) and CD1d tetramer (PE), and were ana-
lyzed by ﬂow cytometry. NKT cell population was identiﬁed as CD19−/CD3+/CD1d tet-
ramer+ cells. (a) Typical dot plots of the splenocyte derived from non-treated mouse,
soluble αGC treated mouse and αGC/R8/PEG-Lip treated mouse. The numbers in the
upper right area indicate the percentage of CD3+/CD1d tetramer+ cells among the
CD19− cells. (b) The percentages of CD19−/CD3+/CD1d tetramer+ cells. Values are
the mean ± SD (n = 3, **P b 0.01).
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cellular internalization is drastically enhanced [13,15,19]. In the case
of αGC, the R8-Lip was also efﬁciently delivered to APCs. Another
point is to control the intracellular trafﬁcking of liposomes. CD1d mole-
cules bind to lipid antigens in endosomes and lysosomes. The CD1dmol-
ecules that contain bound lipid antigens are then delivered to the cellular
membrane and the CD1d molecules present the lipid antigens to NKT
cells. The αGC needs to be released from liposomes and to be present
in endosomes and lysosomes, and we used EPC and Chol in preparing
all liposomes in whichαGC was incorporated in this study. The intracel-
lular trafﬁcking of a cargo in a liposome can be controlled by using differ-
ent lipids. In the case of liposomes containing EPC and Chol, less fusion
occurs with the endosomal or lysosomal membranes. As a result, the li-
posomes remain in the endosomes and lysosomes [15,27]. On the
other hand, dioleoyl phosphatidyl ethanolamine (DOPE)-based lipo-
somes were frequently used for escaping from endosomes and deliver-
ing cargoes to the cytosol [13,28–30]. We also compared the EPC/Chol
based liposome with a fusogenic liposome that was composed of DOPE
in αGC presentation on CD1d of JAWSII cells. As a result, the efﬁciency
of αGC presentation by the DOPE-based liposome was enormously
lower than that of EPC/Chol-based liposome (data not shown). Conse-
quently, this suggests that αGC/R8-Lip efﬁciently induces αGC presen-
tation on CD1d in comparison with soluble αGC.
Contrary to our expectations, the production of IFN-γ in mice that
had been treated with αGC/R8-Lip was similar to that in mice that
had been treatedwith solubleαGC (Fig. 2). That is, nonanoparticulationeffect was observed in vivo. This result indicates that it is insufﬁcient to
merely incorporateαGC into CPP-modiﬁed liposome, such as R8-Lip, to
enhance immune responsemediated byαGC after systemic injection. In
general, liposomes with diameters in the sub-100 nm range have
been used for controlling the biodistribution of drugs, because the
sub-100 nm size of liposomes decreases recognition by the reticulo-
endothelial system and the immune system including APCs [31]. The
size of theαGC/R8-Lip particles was less than 100 nm. It appears that
theαGC/R8-Lip is recognized with difﬁculty by APCs. As another rea-
son, soluble αGC may form a micelle structure, because soluble αGC
used in the in vivo experiments contains Tween20, a detergent.
Hence, the effect of nanoparticulation might be a factor in the case
of soluble αGC, and, as a result, the production of IFN-γ between
αGC/R8-Lip and soluble αGC could be comparable. From the results
shown in Fig. 2, we optimized the αGC/R8-Lip to promote targeting
to the spleen. The spleen is a major target lymphatic organ for immu-
nization via intravenous administration and contains high levels of
APCs. As a result, αGC/R8/PEG-Lip the size of which was around
270 nm induced a signiﬁcantly higher level of production of IFN-γ
than αGC/R8-Lip or soluble αGC (Fig. 3c). In a previous report, we
showed that large sized liposomes (300 nm) accumulate more
efﬁciently in the spleen compared to small sized liposomes (100 nm)
[24]. In this study, αGC/R8/PEG-Lip accumulated at much higher levels
in the spleen compared to αGC/R8-Lip (Fig. 4). Consequently, the
efﬁciency of delivering αGC to APCs might be enhanced by αGC/R8/
PEG-Lip. We also discuss about relationship between particle size and
cellular uptake by APCs. APCs such as DCs and macrophages have a
unique uptake mechanism, termed phagocytosis. Phagocytosis is an
actin-dependent process that involves internalizing particles with
sizes in excess of 0.5 μm [32]. Moreover, the macropinocytosis of DCs
is also unique. Macropinocytosis is a process of “cell drinking” involving
the eruption of membrane rufﬂes from cell surface, which internalizes
particles with sizes up to 5 μm [32,33]. Although macropinocytosis
occurs in all cells as the result of some stimulation, macropinocytosis
constitutively occurs in DCs in contrast to other cell types [33]. Namely,
APCs have a mechanism for the internalization of large particles
(N100 nm) and this mechanism is different from that of normal cells.
However, the relation between liposome size and the efﬁciency of cellu-
lar uptake by APCs was inconsistent [34]. The suitable size seems to be
different depending on the lipid composition, dose, strain, etc. In our
optimization of the size of αGC/R8/PEG-Lip, particularly, αGC/R8/
PEG-Lip prepared using 800-nm of polycarbonate membrane ﬁlters,
we observed a high production of IFN-γ (Fig. 3c). On the other hand,
although the difference in liposome size between 800-nm and 1000-nm
ﬁltered liposomes was small (273 nm and 311 nm), the difference in
IFN-γ production was large (Fig. 3b). As mentioned above, APCs may be
able to take up both types of liposomes viamacropinocytosis. However,
one report indicates that the efﬁciency of cellular uptake of latex parti-
cles by dendritic cells (DCs) starts to decrease from 300 to 400 nm [35].
Thus, the uptake efﬁciency of liposomes into DCs was possibly different
between 273 nm-sized liposomes and 311 nm-sized liposomes. As a
result, the small difference in liposomal size may have affected the ex-
tent of IFN-γ production in this study. The importance of R8 modiﬁca-
tion was also shown in Fig. 3c. These data are entirely consistent with
our previous reports showing that R8-Lip is a potent vaccine delivery
system for lipid antigen presentation and an anti-tumor vaccine in vivo
[13–16]. We thus conclude that R8-Lip is also useful for αGC delivery.
Contrary to R8 modiﬁcation, PEG modiﬁcation resulted in a slight en-
hancement in the production of IFN-γ. Although the ﬁndings suggest
that PEG modiﬁcation had some beneﬁt because the optimal value
of modiﬁcation was present (Fig. 3a), further research will clearly
be needed in this area.
In in vivo animal studies, αGC showed antitumor effects against
various tumors in hepatic and lung metastasis models. However, it
was no longer effective when treatment with soluble αGC started
3 days after the injection of melanoma cells [36,37]. In our study,
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showed no effect against lung metastasis (Fig. 5). To circumvent this
problem, αGC-loaded-DCs were used [7,38,39]. Treatment with
αGC-loaded-DCs efﬁciently inhibited melanoma metastasis, even
when the αGC-loaded-DCs were injected 7 days after injection of
the melanoma cells [38]. However, several administrations were also
necessary in the case of αGC-loaded-DCs. In contrast, the αGC/R8/
PEG-Lip effectively inhibited the lung metastasis of melanoma with
only one injection 4 days after melanoma cell injection (Fig. 5). In addi-
tion, we used B16-F10 cells as model tumor cells for lung metastasis.
B16-BL6 cells have been used in a large number of studies. B16-F10
cells were established by 10 successive selections for lung metastasis
following intravenous injection [40]. B16-BL6 cells were established
from B16-F10 cells that penetrated the mouse bladder membranes
[41]. Although B16-F10 and B16-BL6 cells are both malignant and have
similar characteristics, when the cells are intravenously injected, the
metastasis foci are reported to be greater in the case of B16-F10 than
in B16-BL6 [41,42]. Based on this fact, it appears that B16-F10 more
effectively establishes metastasis. Therefore, we concluded that the
nanoparticulation of αGC with αGC/R8/PEG-Lip drastically improved
the anti-metastatic ability of GC.
NKT cells have been shown to play an important role in antitumor
immune responses. The antitumor effects of αGC are crucially de-
pendent on NKT cells, because no antitumor effects are observed in
NKT cell deﬁcient mice. Immune responses mediated byαGC initiate
αGC presentation on CD1d of APCs. NKT cells then recognizeαGC on
the CD1d of APCs via T cell receptors and speedily produce large
amounts of IFN-γ [4]. These activated NKT cells then expand,
reaching maximal levels at 3 days. Thus, we conﬁrmed αGC presen-
tation on the CD1d of APCs and the expansion of NKT cells which were
critical steps in the immune responses mediated by αGC. αGC/R8/
PEG-Lip signiﬁcantly enhanced αGC presentation on the CD1d of APCs
and the expansion of NKT cells after intravenous administration
(Figs. 6 and 7). The results conﬁrm that the nanoparticulated αGC,
αGC/R8/PEG-Lip in this study, can also activate NKT cells in the general
manner of αGC-mediated immune responses, and can enhance each
process of the αGC-mediated immune responses. The ﬁndings that
the nanoparticulation of αGC drastically enhances immune responses
mediated byαGC via activation of NKT cells may be helpful information
to develop delivery systems incorporating αGC.
The ﬁndings reported herein show that the nanoparticulation of
αGC with αGC/R8/PEG-Lip signiﬁcantly enhanced the presentation
of αGC on the CD1d of APCs, the production of IFN-γ and expansion
of NKT cells, leading to effective anti-metastatic effect in a highly
malignant lung metastasis model, after intravenous administration.
We also revealed that the size control and R8-modiﬁcation in liposo-
mal construction are promising techniques for systemic αGC therapy.
Hence, we conclude that αGC/R8/PEG-Lip can function as a potent
delivery system for αGC therapy via systemic treatment.
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